FDA Approves Meningitis Vaccine After Big Pharma Conducts Human Experiments

FDA Approves Meningitis Vaccine After Big Pharma Conducts Human Experiments









The Food and Drug Administration (FDA) has given GlaxoSmithKilne (GSK) their approval of the MenHibrix vaccine(MHV),
which is meant for infants between the ages of 6 weeks to 18 months.
This vaccine is a dangerous mixture of the meningococcal disease and Hib
disease.

MHV will be manufactured in Rixensart, a Belgium-based arm of GSK Biologicals.

In 2010 and 2011, the FDA rejected MHV. GSK claims that they have
“resolved” the FDA’s concerns about the necessity, potency and
efficiency of MHV. This simply accepted GSK’s word that they have taken
care of the vaccine’s issues. The FDA does not require more proof than
that.

In fact, the FDA’s standard practice is to regulate drugs after they have been approved, rather than just making sure they are safe before releasing them out to the public.

In
2008, the FDA admitted that there is no regulatory checking of safety
of trials. The FDA relied solely on the data provided them from the drug
makers themselves.

Furthermore, the FDA does not check or regulate cosmetics prior to their
release to the markets for the public to purchase. They leave the
safety responsibility to the cosmetic corporations to essentially
regulate themselves.


According to the Centers for Disease Control and Prevention (CDC),
infants are most at risk for contracting bacterial meningitis, which is
an infection that attacks the thin lining surrounding the brain and
spinal cord.

Last month, the CDC was involved in a propaganda campaign to coerce Americans to start receiving immunizations after the recent decline reported by doctors across the country.

Karen Midthum, director of the center for biologics at the FDA stated that:
With
today’s approval of Menhibrix, there is now a combination vaccine that
can be used to prevent potentially life-threatening Hib disease and two
types of meningococcal disease in children. It is the first
meningococcal vaccine that can be given starting as young as six weeks
of age.
The MHV will be administered as a four-dose vaccine that the CDC recommended is added to infant’s immunizations schedule.

Dr. Leo Friedland, vice president of clinical and medical affairs at GSK North American division says:
(Meningitis)
is one of those diseases that although not common, when it occurs it’s
absolutely devastating and horrible. It presents to the doctor when a
child just looks ill, and within 18 to 24 hours, they’re on the deathbed
in the hospital. . . To be able to have a vaccine to prevent meningitis
is really a great day.
The MHV targets only the C and Y strains of meningococcal bacteria and the Hib bacteria (a.k.a. Haemophilus influenzae type b).

• GSK says there is no vaccine in the US to treat the B strain of the meningococcal bacteria.
  
• GSK is planning on administering 1.1 billion doses of MHV to 173 countries in developed and developing countries.
  
• GSK maintains that MHV was evaluated on 7,500 infants and toddlers in the U.S., Mexico and Austria.
  

Pfizer, one of GSK’s biggest competitors, was part of a campaign in Southern Africa and India where they were conducting experiments with their meningitis vaccine on underdeveloped children in nations where their access to healthcare is severely limited.

This experiment was perfectly timed. While a meningitis epidemic broke out in Nigeria,
Pfizer happen to coincide this problem with the reveal of Trovan, which
was distributed to Nigerians in response to the “outbreak”.

To receive the Food and Drug Administration’s certification of approval, Pfizer used Africa as their clinical trial laboratory to produce the proof they needed to make Trovan a profitable endeavor.

The St. Louis University’s (SLU) Center for Vaccine Development (CVD) is conducting a study with Pfizer, to create a vaccine for meningitis specifically targeting children.

Dr. Edwin Anderson, researcher at SLU’s CVD states:
An
effective adolescent vaccine against meningococcal B disease has the
potential to help save lives and reduce emotional and psychological
stress caused by long-term consequences of the disease.
This
vaccine will target the human immune system, our body’s natural defense
against disease. Their purpose is to find an effective way of tricking
the human immune system. Traditional use of dead cultures in this
instance is ineffective, says Anderson.

Because of the adverse reactions, the use of live cultures of dangerous
diseases and the proven ineffectual nature of vaccines, this rush to
find a meningitis vaccine targeting our children is simply another
attempt by Big Pharma to undermine our natural ability to remain
healthy.


Source:-
http://www.activistpost.com/2012/06/fda-approves-meningitis-vaccine-after.html


https://chemtrailawareness.forumotion.co.uk
http://vaccinesdonotwork.blogspot.com/